Format

Send to

Choose Destination
See comment in PubMed Commons below
J Antimicrob Chemother. 2011 Feb;66(2):235-9. doi: 10.1093/jac/dkq448. Epub 2010 Dec 5.

Emerging antiretroviral drug interactions.

Author information

1
Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA. vpham@jhmi.edu

Abstract

With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).

PMID:
21131695
DOI:
10.1093/jac/dkq448
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center